Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TCRT
- Price
- 2.92
- Stock movement up
- +0.06 (2.10%)
- Company name
- Alaunos Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 4.68M
- Ent value
- 3.82M
- Price/Sales
- 779.27
- Price/Book
- 1.72
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -16.90%
- 1 year return
- -82.92%
- 3 year return
- -67.93%
- 5 year return
- -62.19%
- 10 year return
- -46.26%
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TCRT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 0.30 |
| Price to FCF | 0.59 |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 779.27 |
| Price to Book | 1.72 |
| EV to Sales | 636.44 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.60M |
| EPS (TTM) | -7.36 |
| FCF per share (TTM) | 4.97 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.00K |
| Gross profit (TTM) | 2.00K |
| Operating income (TTM) | -7.42M |
| Net income (TTM) | -11.78M |
| EPS (TTM) | -7.36 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 33.33% |
| Operating margin (TTM) | -123633.33% |
| Profit margin (TTM) | -196350.00% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.68M |
| Net receivables | 0.00 |
| Total current assets | 3.55M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 3.55M |
| Accounts payable | 458.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 826.00K |
| Total liabilities | 826.00K |
| Shareholder's equity | 2.72M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 15.67M |
| Capital expenditures (TTM) | 2.25M |
| Free cash flow (TTM) | 7.95M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -432.49% |
| Return on Assets | -331.86% |
| Return on Invested Capital | -432.49% |
| Cash Return on Invested Capital | 291.92% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.05 |
| Daily high | 3.20 |
| Daily low | 2.80 |
| Daily Volume | 136K |
| All-time high | 2400.00 |
| 1y analyst estimate | 1.75 |
| Beta | -0.50 |
| EPS (TTM) | -7.36 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 May 2025 |
Downside potential
Loading...
Downside potential data
| TCRT | S&P500 | |
| Current price drop from All-time high | -99.88% | -12.89% |
| Highest price drop | -99.94% | -56.47% |
| Date of highest drop | 14 Mar 2025 | 9 Mar 2009 |
| Avg drop from high | -75.54% | -11.07% |
| Avg time to new high | 93 days | 12 days |
| Max time to new high | 4939 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
4.68M
Marketcap category
Small-cap
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
Employees
1
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page